TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05609786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized safety planning tool
Description: The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
Study: NCT06284213

Intervention type: OTHER
Intervention: No interventions
Description: This is an observational study with no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: This is an observational study with no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: This is an observational study with no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: This is an observational study with no interventions.
Study: NCT05258071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirepemat
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirepemat
Description: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use
Study: NCT06185205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: High Dose Rate treatment delivery
Study: NCT06532162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine Paracervical Block
Description: A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Paracervical Injection
Description: A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Study: NCT05434702

Intervention type: BEHAVIORAL
Intervention: Digital Diet Diary
Description: Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.

Intervention type: BEHAVIORAL
Intervention: NHANES Food Frequency Questionnaire (FFQ)
Description: Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.

Intervention type: BEHAVIORAL
Intervention: Fitbit data collection
Description: Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.

Intervention type: BEHAVIORAL
Intervention: Quality of Life questionnaire
Description: The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.

Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire
Description: The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.

Intervention type: BEHAVIORAL
Intervention: Godin Exercise Leisure-Time questionnaire
Description: The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).

Intervention type: BEHAVIORAL
Intervention: Zoom interviews
Description: A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
Study: NCT06212999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study: NCT05292846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulation
Description: Apixaban Dabigatran Edoxaban Rivaroxaban
Study: NCT06212999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study: NCT05706311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Tool (Moderate Risk)
Description: Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Tool (High Risk)
Description: Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
Study: NCT05545696

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AI on algorithm
Description: The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AI off algorithm
Description: The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
Study: NCT05706311

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
Study: NCT06591026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Description: One digital helpline session that includes a structured cognitive coping skills brief intervention.
Study: NCT05728450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light amplification by stimulated emission of radiation (LASER)
Description: * The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points
Study: NCT04967833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT06580067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pray Until Something Happens (PUSH)
Description: Self-monitoring of outcomes + alerts/reminders + use of PUSH

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pray Until Something Happens (PUSH)
Description: Self-monitoring of outcomes + alerts/reminders + use of PUSH
Study: NCT05718128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocardiomyocardial biopsy
Description: Endocardiomyocardial biopsy
Study: NCT05240456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta3-Agonists, Adrenergic
Description: The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic drug, Solifenacin
Description: Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
Study: NCT06580067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring of outcomes + alerts/reminder
Study: NCT05237050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound therapy associated with relaxation
Description: Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation alone
Description: Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session).
Study: NCT05318222

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole genome sequencing (WGS)
Description: WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
Study: NCT06101706

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fatigue assessment
Description: FACIT-F questionnaire and Visual Analog Scale for fatigue

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fatigue assessment
Description: FACIT-F questionnaire and Visual Analog Scale for fatigue

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life assessment
Description: PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life assessment
Description: PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Assess severity of psoriatic arthritis
Description: DAPSA score

Intervention type: OTHER
Group type: OTHER
Intervention: Assess severity of cutaneous psoriasis
Description: PASI score
Study: NCT06488183

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
Description: preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
Description: preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
Study: NCT06017557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
Study: NCT05095701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Live Attenuated Varicella Vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Freeze Dired Dilution)
Description: The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
Study: NCT04805736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Image-guided microwave ablation 7-10 days prior to surgery
Study: NCT06507566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tasso+™
Description: The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tasso+™
Description: The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.
Study: NCT05994300

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy
Description: Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2
Study: NCT06462625

Intervention type: OTHER
Intervention: High tibial osteotomy
Description: Correction of lower limb malalignement with tibial bone wedge insertion/removal

Intervention type: OTHER
Intervention: High tibial osteotomy
Description: Correction of lower limb malalignement with tibial bone wedge insertion/removal
Study: NCT04855695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
Study: NCT05068232

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation
Description: Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
Study: NCT05903807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
Study: NCT06478693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-303
Description: MT-303
Study: NCT05585320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-1-104 Monotherapy (Treatment Group A)
Description: Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
Description: Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
Description: Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2
Study: NCT05437055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (Penumbra System with Thunderbolt)
Description: Subject will receive Penumbra System with Thunderbolt
Study: NCT05630872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
Description: Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg orally QD plus TDF/3TC
Description: DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
Study: NCT05588960

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Description: Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch.

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)
Description: Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age.
Study: NCT04433741

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Oxytocin administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Oxytocin administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo administered intravenously
Study: NCT05630872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HPZM
Description: Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HPM
Description: Daily rifapentine-moxifloxacin plus isoniazid regimen
Study: NCT05949788

Intervention type: OTHER
Intervention: No intervention
Description: Retrospect study, no direct intervention

Intervention type: OTHER
Intervention: No intervention
Description: Retrospect study, no direct intervention
Study: NCT06000059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Drama
Description: An hour long radio drama adapted from from a previous community-led theater intervention
Study: NCT05908695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Administered PO
Study: NCT04713969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40mg twice daily
Study: NCT05908695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered PO
Study: NCT05914714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 MG BID Oral Tablet
Description: ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
Study: NCT06521554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-330
Description: Oral Tablet of NVL-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVL-330
Description: Oral Tablet of NVL-330
Study: NCT06091956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6 milligram (mg) orally administrated, twice daily